Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2009 October;57(5) > Minerva Cardioangiologica 2009 October;57(5):597-609

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Cardioangiologica 2009 October;57(5):597-609

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Paclitaxel eluting balloon: from bench to bedside

Marzullo R. 1, Aprile A. 2, Clementi F. 3, Stella P. 4, Modena M. G. 1, Sangiorgi G. M. 1

1 Cardiac Catheterization Laboratory, Department of Cardiology, Policlinic of Modena, Modena, Italy; 2 Cardiovascular Department, Bergamo Hospitals, Bergamo, Italy; 3 Department of Cardiology,Tor Vergata Policlinic, Rome, Italy; 4 Department of Cardiology, Cardiac Catheterization Laboratory, Utrecht, The Netherlands


PDF


Despite the impressive progress of percutaneous treatment modalities, restenosis remains the major Achilles heel of interventional cardiology. Approximately 25% of the general population treated for coronary diseases with a bare-metal stent and about 10% of patients treated with a drug-eluting stent develop an overgrowth of vascular tissue and renarrowing inside the stent, or in-stent restenosis. These rates are even greater in diabetics and patients at higher risk of restenosis both for clinical presentation (patients in dialysis, low ejection fraction) or anatomical characteristics (ostial, bifurcation, long lesions). Non-stent based local drug delivery and particularly the use of paclitaxel eluting balloon (PEB) could be one promising strategy to reduce restenosis. This review will briefly explore the different characteristics of PEB devices currently present in the market and summarize the results obtained both in animal models and clinical practice, giving an indication of the potential field of application of this new technology.

top of page